STOCK TITAN

Revolution Medicines officer proposes $18.7M sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) officer Stephen Kelsey reported a proposed sale of 108,640 common shares, with an aggregate market value of $18,717,585.60 and an approximate sale date of November 16, 2026.

The notice says the shares were and will be received through stock-option exercises over the next three months. It lists August 17, 2026 as the plan adoption or instruction date, if relying on Rule 10b5-1. During the prior three months, Stephen Kelsey reported sales of 5,569 shares for gross proceeds of $1,109,554.38 on September 16, 2026, and 92,531 shares for gross proceeds of $18,724,768.18 on September 11, 2026; the latter is identified as a 10b5-1 sale.

Proposed sale shares 108,640 shares Stephen Kelsey's proposed sale; approximate sale date November 16, 2026
Aggregate market value $18,717,585.60 Proposed sale of 108,640 common shares
Shares outstanding 216,292,323 shares Number outstanding shown in the notice
Prior sale 5,569 shares; gross proceeds of $1,109,554.38 Sale on September 16, 2026
Prior 10b5-1 sale 92,531 shares; gross proceeds of $18,724,768.18 Sale on September 11, 2026
stock options financial
"exercise of stock options"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
aggregate market value financial
"Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares is Stephen Kelsey proposing to sell?

Stephen Kelsey, an officer of Revolution Medicines, reported a proposed sale of 108,640 common shares, with an aggregate market value of $18,717,585.60 and an approximate sale date of November 16, 2026.

How will Stephen Kelsey's proposed RVMD shares be acquired?

The notice says the shares were and will be received upon exercise of stock options over the next three months. The listed plan adoption or instruction date, if relying on Rule 10b5-1, is August 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading